Q-omics provides the consensus-scored TMEM160 profile across patient tissues and cancer cell-line models. TMEM160 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM160 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, TMEM160 RNA expression shows 19,070 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BLCA, and THYM as cancer lineages where TMEM160 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM160 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM160 survival associations across molecular data types. TMEM160 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM160 RNA expression–survival associations across cancer types. High TMEM160 expression shows unfavorable associations in ACC, LGG, PRAD, TGCT and UCS, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM160 RNA expression.
This table summarizes TMEM160 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM160. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM160 shows lower tumor expression in KICH and higher tumor expression in BLCA, COAD, LIHC, HNSC and STAD. The BLCA box plot shows higher TMEM160 RNA expression in tumor versus normal tissue (log2 FC = +0.853, t-test p < 0.001).
This table shows molecular features associated with TMEM160 in patient tissues and cancer cell lines. In patient samples, TMEM160 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM160 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
